potential COVID-19 treatments - versus paracetamol - for COVID-19 (hospitalized or not) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.35 [0.63, 2.89]< 10%1 study (-/1)22.2 %NAnot evaluable crucial-
deaths 1.33 [0.62, 2.84]< 10%1 study (-/1)23.1 %NAnot evaluable crucial-
deaths (time to event analysis only) 1.33 [0.62, 2.84]< 10%1 study (-/1)23.1 %NAnot evaluable crucial-
mechanical ventilation 1.61 [0.52, 4.97]< 10%1 study (-/1)20.3 %NAnot evaluable important-
mechanical ventilation (time to event analysis only) 1.60 [0.51, 5.06]< 10%1 study (-/1)21.2 %NAnot evaluable important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.